A dose-escalation study of large doses of naloxone for treatment of patients with acute cerebral ischemia

Harold P. Adams; Charles P. Olinger; William G. Barsan; Michael J. Butler; Neill R. Graff-Radford; Thomas G. Brott; José Biller; Hanna Damasio; Thomas Tomsick; Mark Goldberg; Judith A. Spilker; Eileen Berljnger; James Dambrosia; Michelle Biros; Renee Hollern

doi:10.1161/01.STR.17.3.404

A dose-escalation study of large doses of naloxone for treatment of patients with acute cerebral ischemia

Harold P. Adams, Charles P. Olinger, William G. Barsan, Michael J. Butler, Neill R. Graff-Radford, Thomas G. Brott, José Biller, Hanna Damasio, Thomas Tomsick, Mark Goldberg, Judith A. Spilker, Eileen Berljnger, James Dambrosia, Michelle Biros, Renee Hollern

Producción científica: Article › revisión exhaustiva

51 Citas (Scopus)

Resumen

A dose-escalation study was performed in 27 patients to determine the highest safe and potentially optimal dose of naloxone for treatment of acute cerebral ischemia. All patients received a bolus of naloxone followed by a continuous 24 hour infusion at an hourly rate 50% of the bolus. Loading doses ranged from 2.5 to 200 mg/m2. Total patient doses ranged from 52.3 to 4978 mg. No major dose-related side effects occurred. This study was not designed to determine naloxone’s efficacy in stroke, but transient or sustained improvement was observed in 13 patients. Three patients’ neurological condition worsened within three hours after the naloxone was discontinued. Our experience suggests that further therapeutic trials of naloxone are worthwhile.

Idioma original	English (US)
Páginas (desde-hasta)	404-409
Número de páginas	6
Publicación	Stroke
Volumen	17
N.º	3
DOI	https://doi.org/10.1161/01.STR.17.3.404
Estado	Published - 1986

ASJC Scopus subject areas

Clinical Neurology
Cardiology and Cardiovascular Medicine
Advanced and Specialized Nursing

Acceder al documento

10.1161/01.STR.17.3.404

Otros archivos y enlaces

Citar esto

Adams, H. P., Olinger, C. P., Barsan, W. G., Butler, M. J., Graff-Radford, N. R., Brott, T. G., Biller, J., Damasio, H., Tomsick, T., Goldberg, M., Spilker, J. A., Berljnger, E., Dambrosia, J., Biros, M., & Hollern, R. (1986). A dose-escalation study of large doses of naloxone for treatment of patients with acute cerebral ischemia. Stroke, 17(3), 404-409. https://doi.org/10.1161/01.STR.17.3.404

Adams, HP, Olinger, CP, Barsan, WG, Butler, MJ, Graff-Radford, NR, Brott, TG, Biller, J, Damasio, H, Tomsick, T, Goldberg, M, Spilker, JA, Berljnger, E, Dambrosia, J, Biros, M & Hollern, R 1986, 'A dose-escalation study of large doses of naloxone for treatment of patients with acute cerebral ischemia', Stroke, vol. 17, n.º 3, pp. 404-409. https://doi.org/10.1161/01.STR.17.3.404

@article{b06a801bf48443c6a84e764f9f168399,

title = "A dose-escalation study of large doses of naloxone for treatment of patients with acute cerebral ischemia",

abstract = "A dose-escalation study was performed in 27 patients to determine the highest safe and potentially optimal dose of naloxone for treatment of acute cerebral ischemia. All patients received a bolus of naloxone followed by a continuous 24 hour infusion at an hourly rate 50% of the bolus. Loading doses ranged from 2.5 to 200 mg/m2. Total patient doses ranged from 52.3 to 4978 mg. No major dose-related side effects occurred. This study was not designed to determine naloxone{\textquoteright}s efficacy in stroke, but transient or sustained improvement was observed in 13 patients. Three patients{\textquoteright} neurological condition worsened within three hours after the naloxone was discontinued. Our experience suggests that further therapeutic trials of naloxone are worthwhile.",

author = "Adams, {Harold P.} and Olinger, {Charles P.} and Barsan, {William G.} and Butler, {Michael J.} and Graff-Radford, {Neill R.} and Brott, {Thomas G.} and Jos{\'e} Biller and Hanna Damasio and Thomas Tomsick and Mark Goldberg and Spilker, {Judith A.} and Eileen Berljnger and James Dambrosia and Michelle Biros and Renee Hollern",

year = "1986",

doi = "10.1161/01.STR.17.3.404",

language = "English (US)",

volume = "17",

pages = "404--409",

journal = "Stroke",

issn = "0039-2499",

publisher = "Wolters Kluwer Health",

number = "3",

}

TY - JOUR

T1 - A dose-escalation study of large doses of naloxone for treatment of patients with acute cerebral ischemia

AU - Adams, Harold P.

AU - Olinger, Charles P.

AU - Barsan, William G.

AU - Butler, Michael J.

AU - Graff-Radford, Neill R.

AU - Brott, Thomas G.

AU - Biller, José

AU - Damasio, Hanna

AU - Tomsick, Thomas

AU - Goldberg, Mark

AU - Spilker, Judith A.

AU - Berljnger, Eileen

AU - Dambrosia, James

AU - Biros, Michelle

AU - Hollern, Renee

PY - 1986

Y1 - 1986

N2 - A dose-escalation study was performed in 27 patients to determine the highest safe and potentially optimal dose of naloxone for treatment of acute cerebral ischemia. All patients received a bolus of naloxone followed by a continuous 24 hour infusion at an hourly rate 50% of the bolus. Loading doses ranged from 2.5 to 200 mg/m2. Total patient doses ranged from 52.3 to 4978 mg. No major dose-related side effects occurred. This study was not designed to determine naloxone’s efficacy in stroke, but transient or sustained improvement was observed in 13 patients. Three patients’ neurological condition worsened within three hours after the naloxone was discontinued. Our experience suggests that further therapeutic trials of naloxone are worthwhile.

AB - A dose-escalation study was performed in 27 patients to determine the highest safe and potentially optimal dose of naloxone for treatment of acute cerebral ischemia. All patients received a bolus of naloxone followed by a continuous 24 hour infusion at an hourly rate 50% of the bolus. Loading doses ranged from 2.5 to 200 mg/m2. Total patient doses ranged from 52.3 to 4978 mg. No major dose-related side effects occurred. This study was not designed to determine naloxone’s efficacy in stroke, but transient or sustained improvement was observed in 13 patients. Three patients’ neurological condition worsened within three hours after the naloxone was discontinued. Our experience suggests that further therapeutic trials of naloxone are worthwhile.

UR - http://www.scopus.com/inward/record.url?scp=0022512423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022512423&partnerID=8YFLogxK

U2 - 10.1161/01.STR.17.3.404

DO - 10.1161/01.STR.17.3.404

M3 - Article

C2 - 3715936

AN - SCOPUS:0022512423

SN - 0039-2499

VL - 17

SP - 404

EP - 409

JO - Stroke

JF - Stroke

IS - 3

ER -

A dose-escalation study of large doses of naloxone for treatment of patients with acute cerebral ischemia

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto